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Background: Fatigue is a disabling syndrome in multiple sclerosis (MS), which may be 
associated with inflammation and faster disease progression.
Objective: To analyze the significance of cognitive fatigue for subsequent disease 
progression.
Method: We followed 46 MS patients and 14 healthy controls in a study over 17 months. 
At the beginning (t1) and at the end (t2) of the study participants scored their fatigue, 
performed the Multiple Sclerosis Functional Composite and received MRI scanning, 
encompassing MPR T1, FLAIR, and DTI sequences. At t1, MS patients were divided 
into those with and those without cognitive fatigue (cut-off score for moderate cog-
nitive fatigue of the Fatigue Scale for Motor and Cognition). We calculated ANCOVAs 
for repeated measurement to analyze the relevance of cognitive fatigue status for the 
number of relapses and for MRI parameters.
results: At t1, but not at t2, patients with cognitive fatigue showed increased axial and 
radial diffusivity of corpus callosum fibers. At t2, these patients showed significantly more 
loss of brain parenchyma and greater enlargement of lateral ventricles. Moreover, they 
developed more relapses, but there was no difference in lesion load or in performance 
deterioration. Additional analyses showed that only cognitive fatigue but not a more 
general score for fatigue (Fatigue Severity Scale) had an impact on the worsening of the 
disease status.
conclusion: Patients with cognitive fatigue may develop more brain atrophy and 
relapses during the next 17  months than patients without cognitive fatigue. Hence, 
experiencing cognitive fatigue might indicate more aggressive inflammatory processes 
and subsequent neurodegeneration.
Keywords: multiple sclerosis, cognitive fatigue, Mri, brain atrophy, diffusion tensor imaging, disease progression, 
follow-up study
Abbreviations: BDI, Beck’s Depression Inventory; DTI, diffusion tensor imaging; FSMC, Fatigue Scale for Motor and Cognitive 
Functions; FSS, Fatigue Severity Scale; MSFC, Multiple Sclerosis Functional Composite; NEX, Number of excitations; PASAT, 
Paced Auditory Serial Addition Test.
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inTrODUcTiOn
Fatigue is a common disabling syndrome in multiple sclerosis 
(MS), which has been related to increased inflammation and 
faster disease progression (1). Recently, various authors proposed 
that fatigue may denote increased levels of proinflammatory 
cytokines and, therefore, an increased risk of T-cells invading the 
central nervous system (2–4). Previous studies examining this 
relation between fatigue and disease progression revealed incon-
sistent results. One study followed 11 MS patients for 3 months, 
performing serial MRI scans every 4  weeks (5). Gadolinium-
enhancing lesions were unrelated to fatigue, arguing against a 
prognostic value of fatigue. A recent study on 127 patients with 
a clinically isolated syndrome revealed that patients with fatigue 
have a significantly higher chance to convert to MS (according to 
the McDonald criteria) than patients without fatigue (6), arguing 
for a prognostic value of fatigue.
Three studies analyzed the relation between fatigue and brain 
atrophy. One relied on retrospective scores of fatigue levels dur-
ing the last 3 months and revealed no significant relation between 
fatigue and brain atrophy (7). Two studies used a prospective 
design and examined changes in brain atrophy over more than 
4 years (8, 9). Both studies found that MS patients with fatigue 
suffered subsequently from enhanced brain atrophy.
Comparing these five studies, all used different fatigue 
measures and none focused on cognitive fatigue. Fatigue is a 
multi-componential symptom, which may encompass impair-
ment related aspects [sometimes termed “fatigability” (1)] and 
the subjective experience of inflammation [a feature of sickness 
behavior (10)]. This distinction partly reflects the differentia-
tion between motor fatigue, which seems to be related to motor 
impairment, and cognitive fatigue, which is a feeling independent 
of prior effort. Traditional scales, e.g., the Fatigue Severity Scale 
(FSS), used in most studies on fatigue and relapses or disease pro-
gression (11–13), do not differentiate between motor fatigue and 
cognitive fatigue. To study whether fatigue as feature of sickness 
behavior may indicate increased inflammation and more severe 
disease progression, scales assessing cognitive fatigue specifically 
should be used.
Neuropathological processes in MS are not restricted to 
gadolinium-enhancing lesions, but may also involve subclinical 
activation of glia cells, low level inflammation, and Wallerian 
degeneration. They might also be accompanied by partial 
remyelination of axons. The analysis of such processes requires 
quantified MRI analysis, focusing on changes in molecular diffu-
sion as well as volumetry of brain parenchyma and the ventricles. 
Diffusion tensor imaging (DTI) offers the opportunity to study 
demyelination in normal appearing white matter. The corpus cal-
losum, being composed of densely packed nerve fibers, seems to 
be well suited for DTI-analysis of disease progression in MS. For 
instance, Harrison et al. showed that radial diffusivity, calculated 
for the corpus callosum, is very sensitive to disease-related changes 
compared to other MRI measures (14). Moreover, changes in 
radial diffusivity can be well determined in small patient groups 
already after 1 or 2 years. Other studies have shown that brain and 
ventricle volumetry offer the possibility to measure longitudinal 
changes in MS patients (15).
In a prospective study, we examined the relation between 
 cognitive fatigue and disease progression in MS patients, which 
were assessed twice with an interval of 17 months. We hypoth-
esized that baseline cognitive fatigue levels might influence 
neurodegeneration, measured by changes in brain volume, and 
subclinical inflammation, as measured by axial and radial dif-
fusivity of the corpus callosum.
MaTerials anD MeThODs
Participants
Based on the power calculation of Harrison et  al. (14), we 
included 46 MS patients and 14 healthy controls. Patients were 
recruited from self-help groups or they were patients of neurolo-
gists in Bremen and surroundings. They were aged between 18 
and 46 years, diagnosed with a relapsing-remitting or secondary 
progressive MS according to the McDonald Criteria (16) and had 
an Expanded Disability Status Scale (17) of 0-6.5. Patients with a 
relapse during the 4 weeks before the investigation were excluded.
Age, education, and gender matched healthy controls were 
mainly recruited from the nursing staff of the Klinikum Bremen-
Ost as well as from the staff of the Fraunhofer MEVIS Institute. 
Participants confirmed not to have any neurological or psychiat-
ric disorders.
All participants gave their informed consent. The Ethical 
Board of the Bremer Physicians Society approved the study.
assessment of clinical Data
To assess MS-related fatigue, the Fatigue Scale for Motor 
and Cognitive Functions (FSMC) was applied. The FSMC is 
composed of 20 items and evaluates two main components of 
fatigue, namely motor and cognitive fatigue (18). Additionally, 
we applied the FSS (12). Beck’s Depression Inventory (BDI) 
was applied to assess depressive mood, but items that assess 
somatic concerns associated with depression were excluded, 
because of their overlap with experiencing fatigue (19, 20). As 
a measure of the clinical status (leg and arm function as well 
as cognitive functioning) we included the Multiple Sclerosis 
Functional Composite (MSFC). The subtest Paced Auditory 
Serial Addition Test (PASAT) of the MSFC was included to 
measure cognitive functioning (21). Participants were assessed 
twice (t1, t2) with a delay of 17 months. Finally, at t2, we asked 
patients about the occurrence of relapses during the evaluation 
period.
image acquisition
A 3.0T scanner (Siemens Skyra, Erlangen, Germany) was used 
to attain magnetic resonance images of the brain. By using 64 
non-collinear orientations in the axial plane [image resolution 
2 mm × 2 mm × 2 mm, ~55 slices, TR = 7600, TE = 90, number of 
excitations (NEX) = 1, b-value = 1000, scanning time ~9 min], dif-
fusion MRI images were obtained. To receive T1-weighted images 
(TR = 1900, TE = 2.43) and FLAIR-weighted images (TR = 5000, 
TE = 388), an isotropic resolution of 1 mm × 1 mm × 1 mm was 
used. These were also used to investigate brain atrophy measures 
and lesion segmentations.
TaBle 1 | Baseline characteristics and Fss, eDss, BDi, and FsMc  
(total, cognition, and motor subscales) outcome for the healthy controls 
and the two patient groups.
control 
group
no cognitive 
fatigue
cognitive 
fatigue
Sex (females/males), n (%) 9/4 (69.2%) 9/5 (64.3) 18/10 (64.3)
Clinical phenotype n (%)
Relapsing-remitting N/A 12 (85.7) 18 (64.3)
Secondary progressive 2 (14.3) 10 (35.7)
No medication/interferons/
escalated medications (%)a
100/0/0 15.4/53.8/30.8 46.7/40.0/13.3
Age (years) (mean, SD)a 48.6 (5.0) 42.8 (12.8) 50.5 (8.8)
Education (years) (median, R)a 13.0 (5.0) 12.5 (3) 10.0 (5.0)
FSS (mean, SD)a 19 (9.87) 29 (10.25) 46 (10.64)
FSMC cognition (median, R) 17.0 (26) 21.0 (14) 36.5 (21)
FSMC motor (mean, SD) 15.5 (6.5) 26.21 (6.9) 38.93 (6.1)
Relapses during the evaluation 
perioda
N/A 1 out of 14 13 out of 28
Relapsing-remitting N/A 2 out of 12 9 out of 18
Secondary progressive N/A 1 out of 2 2 out of 10
FSS, Fatigue Severity Scale; FSMC, Fatigue Scale for Motor and Cognitive Functions; 
MS, multiple sclerosis.
aSignificant differences between the MS groups computed as described above.
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Measurement of lesion load, Brain 
atrophy, and corpus callosum
Analysis of the MRI data was performed using the NeuroQLab3.531 
software package (Fraunhofer MEVIS, Bremen, Germany). We 
calculated lesion load using the FLAIR images. For calculation 
of gray and white matter volume (total brain volume, TBV), the 
brain parenchymal fraction (BPF) and the volume of the lateral, 
third, and fourth ventricles T1-weighted images were used.
T1-weighted images were also utilized to compute the corpus 
callosum index (CCI). For regional measurements, we split the 
corpus callosum into three segments (anterior, middle, poste-
rior), and divided each by the anterior–posterior diameter of the 
corpus callosum [see Yaldizli et al. (22)].
Fiber Tractography and Quantification
The advection–diffusion-based algorithm was used for tracking 
fibers (23). For the corpus callosum, the seed region was defined in 
a sagittally oriented slice located above the lateral ventricles. Two 
parts of the corpus callosum were tracked separately, in particular 
the frontal part (from the frontal tip to vertex) and the posterior 
part (from vertex to back tip). To quantify each part, two crop 
ROIs were defined in sagittally oriented slices at the points where 
fibers run caudally to merge with pyramidal tracts. Mean values 
of axial and radial diffusivity were calculated for each participant. 
A detailed description of the quantification method can be found 
in Klein et al. (24).
statistical analysis
We split the MS group in a group without cognitive fatigue and a 
group with cognitive fatigue, according to the Manual of the FSMC, 
using 28 as cut-off score for moderate cognitive fatigue (18).
To compare the groups at t1, parametrical and non-parametri-
cal tests were used depending on the data-distributions, analyzed 
with the Kolmogorov–Smirnov test.
We used a repeated measurement ANCOVA to analyze the 
impact of cognitive fatigue on MRI parameters and performance 
scores. TIME (t1 and t2) served as within-subject variable and 
GROUP (healthy controls, MS patients with and without cogni-
tive fatigue) as between subject variable. We included AGE as a 
covariate since age is associated with a decline of brain volume 
and ventricle size. The DTI measures axial and radial diffusivity 
were used as within subject variable in a repeated measurement 
ANCOVA. Post hoc analysis of interaction effects was per-
formed with difference scores for significant MRI variables. For 
post hoc testing, we used the Bonferroni correction for multiple 
comparisons.
To check for influences of the clinical phenotype of MS, the 
same analyses were also performed separately for relapsing-
remitting MS patients and for secondary progressive MS patients.
To get an idea of the effects of cognitive fatigue in comparison 
to those of moderate motor fatigue or moderate global fatigue 
[FSS, which has been used in previous studies (11–13)], we 
repeated the above-mentioned analyses, splitting MS patients in 
a group with a motor fatigue score less than 27 and a group with a 
score of 27 and higher (18), as well as in a group with an FSS score 
of less than 5 and a group with a score of 5 and higher (12). At the 
same time, it should be noted that our study was not designed for 
and does not allow a direct comparison between different aspects 
of fatigue.
resUlTs
groups characteristics at t1
After drop out of four patients from the MS group and one 
participant from the control group at t2, the data of 42 patients 
and 13 controls were analyzed. Reasons for drop out were a preg-
nancy, familial problems, relocation without actualization of the 
address (n = 2) and a withdrawal of the agreement to participate. 
Baseline characteristics of the patients and the control group are 
shown in Table 1.
The comparison of MS patients with and without cogni-
tive fatigue revealed no significant differences in gender ratio. 
Furthermore no differences were found in terms of the number 
of patients suffering from progressive and non-progressive types 
of MS as well as for the EDSS score and the total lesion load. 
The number of MS patients, receiving disease-modifying drugs, 
divided into those with classical interferons and those receiving 
escalating treatments with Natalizumab or Fingolimod, failed to 
reach significance [χ(2) = 4.827, p = 0.089] (see Table 1).
The two patients groups differed in age [F(25.437) = −2.378, 
p = 0.026] and BDI score [F(1) = 6.675, p = 0.010], FSS score 
[F(1) = 15.752, p < 0.001] (see Table 1).
cognitive Fatigue status at t1  
and Disease Progression
Table 2 gives an overview of the following results.
Significantly more patients with cognitive fatigue suffered 
relapses during the 17  months interval than patients without 
cognitive fatigue [χ(1) = 5.027, p = 0.018].
TaBle 2 | Mean and sD as well as the main and interaction effects given by the ancOVa for repeated measurements controlling for age for the group 
with and without cognitive fatigue as well as for the control group.
cognitive fatigue (n = 28) no cognitive fatigue (n = 14) healthy controls (n = 13) sign.
T1 T2 T1 T2 T1 T2
Mean (sD) Mean (sD) Mean (sD) Mean (sD) Mean (sD) Mean (sD)
BDI 7.39 (6.53) 5.39 (6.34) 2.71 (2.53) 2.00 (1.92) 3.23 (4.44) 1.92 (2.22) a, b
EDSS 4.14 (1.52) 3.70 (1.46) 2.63 (2.12) 3.42 (2.00) N/A N/A b
MSFC −0.15 (0.53) −0.02 (0.50) −0.01 (0.48) 0.09 (0.60) 0.47 (0.41) 0.57 (0.34) a
PASAT 43.67 (13.11) 47.89 (9.10) 45.07 (8.41) 45.93 (11.26) 47.77 (10.32) 51.54 (11.23)
Lesion load 6.94 (14.86) 7.03 (15.07) 3.25 (2.71) 3.21 (2.63) 0.03 (0.08) 0.07 (0.18) b
TBV 1221.1 (125.01) 1199.8 (120.43) 1191.2 (118.33) 1190.0 (117.86) 1280.9 (72.55) 1275.3 (75.80) c
BPF 0.81 (0.04) 0.79 (0.04) 0.82 (0.04) 0.81 (0.04) 0.85 (0.15) 0.84 (0.02) a
Lateral ventricles 40.24 (29.29) 41.60 (29.75) 33.61 (26.33) 33.26 (26.09) 16.78 (6.43) 16.88 (6.80) a, c
Volume of third and fourth ventricle 4.13 (1.40) 4.21 (1.40) 2.99 (1.46) 3.24 (1.39) 2.72 (1.27) 2.85 (1.31) a, b
CCI 0.33 (0.08) 0.36 (0.07) 0.33 (0.70) 0.37 (0.07) 0.43 (0.05) 0.45 (0.04) a
Axial and radial diffusivity of the 
corpus callosum
0.0013 (0.0001) 0.0014 (0.0002) 0.0013 (0.0001) 0.0013 (0.0002) 0.0012 (0.0000) 0.0012 (0.0001) a, c
BDI, Beck’s Depression Inventory; BPF, brain parenchymal fraction; CCI, corpus callosum index; EDSS, Expanded Disability Status Scale; FSMC, Multiple Sclerosis Functional 
Composite; MS, multiple sclerosis; PASAT, Paced Auditory Serial Addition Test; TBV, total brain volume.
Significant difference (p < 0.05) for a: main factor GROUP, b: significant main factor TIME, c: significant interaction group × time.
4
Sander et al. Cognitive Fatigue and Brain Parenchymal Loss
Frontiers in Neurology | www.frontiersin.org September 2016 | Volume 7 | Article 155
For the EDSS only a significant main effect for TIME 
[F(1,37) = 16.435, p < 0.001] and an interaction effect between 
TIME and AGE [F(1,37) = 16.327, p < 0.001] were found.
The analysis of the MSFC data revealed a significant main 
effect for Group [F(2,48) = 8.25, p = 0.001], but no significant 
main effect of TIME and no interaction effect. The patient group 
had a significantly lower MSFC score than the control group but 
there was no significant difference between the patient groups, as 
post hoc analysis revealed. A separate analysis of the Subtest PASAT 
of the MSFC did reveal a main effect for AGE [F(1,50) = 4.402, 
p = 0.041] but no significant other main or interaction effects.
A main effect for TIME was found for the mental items of 
the BDI [F(1,51) = 6.109, p = 0.017]. The BDI score of the total 
group decreased significantly over time. A main effect of GROUP 
was found [F (2,51) = 4.023, p = 0.024] too, but no interaction 
with TIME. Post hoc analysis revealed that patients with cognitive 
fatigue had a significantly higher score for the mental items of 
the BDI than patients without cognitive fatigue and the control 
group. The scores of the patient group without fatigue and the 
control group were not significantly different.
Concerning the MRI parameters, significant main effects for 
GROUP were found for the axial and radial diffusivity of the cor-
pus callosum [F(2,51) = 6.67, p = 0.003], the BPF [F(2,51) = 5.85, 
p = 0.005], the CCI [F(2,51) = 11.41, p = 0.001], the lateral ventri-
cles [F(2,51) = 4.12, p = 0.022] and the third and fourth ventricle 
[F(2,51) = 4.48, p = 0.016]. Post hoc analyses revealed significant 
differences between the patient groups and the control group, but 
not between the patient groups. The patient group had higher 
axial and radial diffusivity of the corpus callosum, a lower BPF, 
a lower CCI and higher volumes of the lateral, third, and fourth 
ventricles compared to the control group.
Significant main effects for TIME were found for the third and 
fourth ventricle volume [F(1,50) = 4.125, p = 0.048]. The volume 
of the ventricles increased in all three groups.
Significant AGE effects were obtained for the parameter TBV 
[F(1,51) = 5.137, p = 0.028].
Interaction effects between GROUP and TIME were found 
for the lateral ventricles [F(2,51) = 4.123, p = 0.022] (Figure 1), 
the TBV [F(2,51) =  5.328, p =  0.008] (Figure 2) and the axial 
and radial diffusivity of the corpus callosum [F(2,51) =  3.722, 
p = 0.031].
Bonferroni corrected multiple comparisons among groups of 
changes in lateral ventricle volume revealed a significant difference 
between patients with and without cognitive fatigue (1.37 ± 1.98 
vs. 0.37±  2.01  ml, p =  0.019). No significant differences were 
found between the MS group without fatigue and the control 
group (p < 0.999) and the MS group with fatigue and the control 
group (p = 0.143) (see Table 3). Using the less conservative LSD 
post hoc test, the difference between the control group and the MS 
patient group with cognitive fatigue was significant for the lateral 
ventricles (p = 0.048), as well as for the TBV (p = 0.021).
Concerning the change in TBV, post  hoc testing revealed 
a significant difference between the MS group with cognitive 
fatigue [−21.24 ±  16.78  ml] and the group without cognitive 
fatigue [−0.37 ± 2.01 ml, p = 0.010]. No significant differences 
were found for the comparison of the two MS groups with the 
control group (see Table 3).
There were no significant differences between all three groups 
for the axial and radial diffusivity of the corpus callosum using 
the Bonferroni correction (see Table 3). But the less conserva-
tive LSD post hoc tests revealed significant differences between 
both MS groups concerning the axial and radial diffusivity of the 
corpus callosum (p = 0.038) and between the control group and 
the MS group with fatigue (p = 0.038).
Comparing MS Patients with and without Cognitive 
Fatigue According to Their Clinical Phenotype
Table 4 gives an overview of the following results.
FigUre 1 | The mean of the volume of the lateral ventricles is shown for each group and time point t1 and after 17 months (t2).
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Analyzing the data only for relapsing-remitting MS 
patients (n =  30), the MSFC showed a main effect of GROUP 
[F(2,37)  =  7.468, p  =  0.002], but we did not find any other 
significant group effects for clinical variables (Table 4 gives an 
overview of the results). Post hoc analyses revealed significant 
differences between the patient groups and the control group, but 
not between the patient groups.
Analysis of the MRI parameters revealed main effects 
for GROUP for the BPF [F(2,39)  =  4.029, p  =  0.026], the 
CCI [F(2,39)  =  9.355, p  <  0.001] and the DTI measures 
[F(2,39) = 6.331, p = 0.004], all pointing to a higher impairment 
of the patient group compared to the control group.
Main effects for TIME were found for the CCI [F(1,39) = 12.799, 
p = 0.001] and the third and fourth ventricle [F(1,39) = 7.188, 
p = 0.011].
Interaction effects between GROUP and TIME were found 
for the TBV [F(2,39) = 4.100, p = 0.024], but there were no sig-
nificant differences between all three groups for the TBV using 
the Bonferroni corrected multiple comparisons as well as the less 
conservative LSD post hoc test.
None of the other clinical or MRI variables showed an interac-
tion effect of GROUP and TIME.
Only two of the 12 patients with a secondary chronic disease 
course did not suffer from at least moderate fatigue. Therefore, 
the statistical comparison between patients with and without 
fatigue was canceled.
Motor or global Fatigue status at t1  
and Disease Progression
Comparing MS Patients with and without Motor 
Fatigue
There was no significant difference in relapse rate comparing 
patients with and without motor fatigue.
Table 5 gives an overview of the following results.
A main effect for the mental items of the BDI was found for 
TIME [F(1,51) = 4.754, p = 0.034], showing a decline of the BDI 
scores of the total group over time. Additionally, a main effect of 
TIME was found for the EDSS [F(1,37) = 17.594, p < 0.001] as 
well as a main effect of GROUP [F(2,37) = 6.418, p = 0.016] and 
an interaction effect between TIME and AGE [F(1,37) = 17.159, 
p < 0.001]. The patient group with motor fatigue had a higher 
EDSS than the patient group without motor fatigue.
A main effect for GROUP was found for the MSFC 
[F(2,48)  =  8.253, p  =  0.001]. The MSFC score was lower in 
patients without motor fatigue, compared to the patients with 
motor fatigue and also compared to the group of healthy controls, 
who had the highest scores.
The analyses on patients with and without motor fatigue 
also showed significant main effects for GROUP for the BPF 
[F(2,51) = 5.800, p = 0.0005], the lateral ventricles [F(2,51) = 3.591, 
p  =  0.035], the third and fourth ventricles [F(2,51)  =  3.643, 
p = 0.033], the CCI [F(2,51) = 11.444, p < 0.001] and the DTI 
measures [F(2,51) = 6.708, p = 0.003]. Post hoc analyses revealed 
TaBle 3 | Mean and sD of the differences between t1 and t2 given for variables with the significant interaction effects in the ANCOVA analysis.
control group no cognitive fatigue cognitive fatigue
Mean sD Mean sD Mean sD
TBVa,b 5.59 14.11 1.50 27.84 21.24 16.78
Lateral ventriclesa,b −0.10 1.42 −0.37 2.01 −1.37 1.98
Axial and radial diffusivity of the corpus callosumb,c 0.0000360 0.0000670 0.0000416 0.0000702 0.0000202 0.0000872
TBV, total brain volume.
aSignificant differences between both MS groups using Bonferroni post hoc test.
bSignificant differences between control group and MS group with fatigue using LSD post hoc test.
cSignificant differences between both MS groups using LSD post hoc test.
FigUre 2 | Mean of the total brain volume (TBV) is displayed for each group and time point t1 and after 17 months (t2).
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significant differences between the patient groups and the control 
group, but not between the patient groups. The patient group 
had a lower BPF, a higher volume of the ventricles, a lower CCI, 
and a higher axial and radial diffusivity of the corpus callosum 
compared to the healthy controls.
Significant main effects for TIME were found for the CCI 
[F(1,51) = 13.086, p = 0.001]. No significant interaction effects 
between TIME and GROUP were found for any of the variables.
Comparing MS Patients with and without  
Fatigue Using the FSS
There was no significant difference in relapse rate between 
patients with and without fatigue according to the FSS.
Table 6 gives an overview of the following results.
The analyses also showed no main or interaction effects for 
the mental items of the BDI, BPF, TBV, lateral ventricle volume, 
third and fourth ventricle volume, lesion load, axial and radial 
diffusivity, and the MSFC, including the PASAT.
There was a main effect of TIME for the CCI [F(1,39) = 11.019, 
p =  0.002], which increased over time in all three groups. For 
the EDSS, we found a main effect of TIME [F(1,37) =  15.394, 
p < 0.001] as well as a main effect of GROUP [F(1,37) = 6.795, 
p =  0.013]. The EDSS score of the total group decreased over 
time. The EDSS score of the patients with fatigue was higher than 
the EDSS score of the patients without fatigue. An interaction 
effect between TIME and AGE [F(1,37) = 16.829, p < 0.001] was 
found too.
TaBle 4 | Mean and sD and the main and interaction effects given by the ancOVa for repeated measurements controlling for age for the group with and without cognitive fatigue separated 
according to the progress form of Ms.
rr cognitive fatigue (n = 18) rr no cognitive fatigue (n = 12) sign. scP cognitive fatigue (n = 10) scP no cognitive fatigue (n = 2)
T1 T2 T1 T2 T1 T2 T1 T2
Mean (sD) Mean (sD) Mean (sD) Mean (sD) Mean (sD) Mean (sD) Mean (sD) Mean (sD)
BDI 7.39 (7.09) 5.38 (7.27) 3.00 (2.6) 2.08 (2.07) 7.40 (5.74) 5.60 (4.55) 1.00 (1.41) 1.50 (0.71)
EDSS 3.64 (1.41) 3.69 (1.63) 2.15 (1.94) 3.35 (2.12) 5.05 (1.34) 3.70 (1.18) 5.00 (1.41) 3.75 (1.77)
MSFC −0.06 (0.50) 0.11 (0.43) 0.06 (0.48) 0.18 (0.59) a −0.33 (0.60) −0.26 (0.56) −0.38 (0.40) −0.43 (0.52)
PASAT 44.47 (13.27) 48.35 (9.11) 45.08 (8.78) 46.08 (11.62) 42.30 (13.43) 47.10 (9.53) 45.00 (8.49) 45.00 (12.73)
Lesion load 4.07 (7.15) 4.11 (7.22) 2.93 (2.77) 2.87 (2.64) 12.10 (22.80) 12.28 (23.14) 5.11 (1.68) 5.28 (1.83)
TBV 1223.38 (147.16) 1199.35 (140.90) 1222.29 (107.99) 1219.26 (108.11) c 1192.42 (72.75) 1176.20 (75.00) 1141.25 (206.12) 1148.95 (208.67)
BPF 0.83 (0.04) 0.81 (0.04) 0.82 (0.04) 0.81 (0.05) a 0.78 (0.03) 0.77 (0.03) 0.82 (0.02) 0.81 (0.02)
Lateral ventricles 28.97 (19.28) 30.41 (20.00) 31.37 (28.50) 31.59 (28.32) 62.26 (32.87) 63.51 (33.41) 37.65 (3.07) 33.76 (4.42)
Volume of third and fourth ventricle 3.68 (1.17) 3.74 (1.16) 2.89 (1.53) 3.17 (1.43) 4.93 (1.46) 5.07 (1.45) 3.63 (1.06) 3.67 (1.47)
CCI 0.36 (0.06) 0.39 (0.05) 0.33 (0.06) 0.38 (0.07) a 0.26 (0.04) 0.29 (0.05) 0.32 (0.06) 0.31 (0.08)
Axial and radial diffusivity of the corpus callosum 0.0013 (0.0001) 0.0012 (0.0001) 0.0013 (0.0001) 0.0013 (0.0002) a 0.0015 (0.0001) 0.0014 (0.0002) 0.0014 (0.0001) 0.0014 (0.0001)
BDI, Beck’s Depression Inventory; BPF, brain parenchymal fraction; CCI, corpus callosum index; EDSS, Expanded Disability Status Scale; FSMC, Multiple Sclerosis Functional Composite; MS, multiple sclerosis; PASAT, Paced Auditory 
Serial Addition Test; TBV, total brain volume; RR, relapsing-remitting MS; ScP, secondary progressive MS.
Significant difference (p < 0.05) for a: main factor GROUP, b: significant main factor TIME, c: significant interaction group × time.
TaBle 5 | Mean and sD and the main and interaction effects given by the ancOVa for repeated measurements controlling for age for the group with and without motor fatigue.
Motor fatigue (n = 32) no motor fatigue (n = 9) healthy controls (n = 13) sign.
T1 T2 T1 T2 T1 T2
Mean (sD) Mean (sD) Mean (sD) Mean (sD) Mean (sD) Mean (sD)
BDI 6.73 (6.26) 4.88 (5.99) 2.56 (2.79) 2.00 (2.06) 3.23 (4.44) 1.92 (2.22) b
EDSS 4.10 (1.59) 3.74 (1.44) 2.28 (2.02) 3.17 (2.17) N/A N/A a, b
MSFC −0.13 (0.54) 0.013 (0.53) −0.00 (0.48) 0.04 (0.58) 0.47 (0.41) 0.57 (0.34) a
PASAT 43.94 (12.32) 48.38 (8.99) 44.89 (9.35) 43.11 (11.91) 47.77 (10.32) 51.54 (11.23)
Lesion load 6.42 (13.74) 6.50 (13.93) 3.11 (2.91) 3.03 (2.75) 0.03 (0.08) 0.07 (0.18)
TBV 1206.32 (124.42) 1190.68 (121.67) 1231.833 (114.05) 1220.76 (109.06) 1280.9 (72.55) 1275.3 (75.80)
BPF 0.81 (0.04) 0.80 (0.04) 0.82 (0.05) 0.80 (0.05) 0.85 (0.15) 0.84 (0.02) a
Lateral ventricles 38.58 (27.79) 39.47 (28.36) 35.84 (31.82) 36.29 (31.48) 16.78 (6.43) 16.88 (6.80) a
Volume of third and fourth ventricle 3.94 (1.39) 4.07 (1.38) 3.04 (1.76) 3.23 (1.61) 2.72 (1.27) 2.85 (1.31) a
CCI 0.33 (0.07) 0.36 (0.07) 0.33 (0.06) 0.37 (0.07) 0.43 (0.05) 0.45 (0.04) a, b
Axial and radial diffusivity of the corpus callosum 0.0013 (0.0001) 0.0013 (0.0001) 0.0013 (0.0001) 0.0013 (0.0001) 0.0012 (0.0000) 0.0012 (0.0001) a
BDI, Beck’s Depression Inventory; BPF, brain parenchymal fraction; CCI, corpus callosum index; EDSS, Expanded Disability Status Scale; FSMC, Multiple Sclerosis Functional Composite; MS, Multiple Sclerosis; PASAT, Paced 
Auditory Serial Addition Test; TBV, total brain volume.
Significant difference (p < 0.05) for a: main factor GROUP, b: significant main factor TIME, and c: significant interaction group × time.
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There was no interaction effect between GROUP and TIME 
for any of the analyzed variables.
DiscUssiOn
The main findings show that patients with at least moderate 
cognitive fatigue had an increased axial and radial diffusivity in 
the corpus callosum, an increased volume of the lateral ventricle 
and a decreased brain volume (gray and white matter volume) 
after 17 months compared to a group of healthy controls and, 
more importantly, to a group of MS patients without cognitive 
fatigue.
These findings suggest that increased cognitive fatigue at t1 
may be a prognostic marker for disease progression and this has 
not been shown in any previous study. Our findings underscore 
those of Runia et  al. (6), showing that patients with clinically 
isolated syndrome suffering from fatigue have a greater risk to 
convert to clinically definite MS. It is noteworthy that the MS 
group with cognitive fatigue more often suffered from relapses 
during the interval than the group without cognitive fatigue 
(Table 1) and that this difference is significant.
Experiencing relatively high levels of fatigue, reflecting the 
subjective component of sickness behavior (2), may indicate 
more aggressive inflammatory processes at t1 leading to loss 
of brain volume at t2. Accordingly, changes from t1 to t2 were 
significant for lateral ventricle size and TBV for the MS patients 
with cognitive fatigue but not for lesion load, CCI, and BPF 
(although the absolute figures pointed in the right direction). 
These findings basically replicate findings from two prospective 
studies, but there are also relevant differences (8, 9). First, the 
interval in our study was 17 months, which is much shorter than 
in the two previous studies. Hence, according to our results the 
long-term significance of fatigue can be measured in a period 
that approximately matches the interval used for routine clinical 
scanning. Second, in contrast to other studies, we focused on 
TBV and lateral ventricle size. The latter is highly influenced 
by an increasing periventricular lesion load and the so-called 
Dawson fingers. Therefore, the size of the lateral ventricles 
should be a very sensitive marker for disease progression. TBV 
reflects brain volume directly, BPF as fraction of cranial volume. 
Changes in BPF, therefore, are influenced by two measurement 
errors, that of brain volume and of cranial volume. Because 
a standardized measure of brain volume is less important for 
longitudinal studies, in a longitudinal design TBV seems prefer-
able; whereas in cross-sectional studies, BPF seems the better 
measurement.
Cognitive fatigue at t1 was related to increased axial and 
radial diffusivity in the corpus callosum. In a previous study, we 
also found increased values for axial and radial diffusivity in the 
corpus callosum of MS patients, but there we did not analyze 
its relation to fatigue (25). Increased radial diffusivity has been 
related to demyelination, allowing water molecules to move in 
vertical direction of myelinated axons. During inflammation, 
axial diffusivity is usually decreased, because of swelling and 
inflammation [see also Fink et al. (25)]. But in later stages axial 
diffusivity may increase indicating either recovery or Wallerian 
degeneration. Interpretation of increased axial diffusivity is, 
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therefore, difficult. Here, we compared the MS groups with and 
without cognitive fatigue directly with a healthy control group 
and we found no threefold interaction between GROUP, TIME, 
and DIFFUSIVITY, but only an interaction between GROUP 
and TIME. MS patients without fatigue and healthy controls 
showed a similar increase in axial and radial diffusivity over time, 
whereas MS patients with fatigue started with higher axial and 
radial diffusivity scores but decreased in diffusivity over time. 
The higher axial and radial diffusivity at t1, therefore, seems to 
be the critical finding for the group with cognitive fatigue and 
not the lower score at t2 (as in the case of brain atrophy). The 
increase in diffusivity may, therefore, indicate increased demy-
elination at t1, which may have terminated at t2, where it could 
be measured as increased ventricle volume and loss of white and 
gray matter.
This interpretation seems to hold for MRI parameters, but 
not for performance measures. Three previous studies with more 
patients than in our study and focusing on the clinical relation 
between fatigue and disease progression yielded similar negative 
results for performance scores (11, 13, 26). One of these studies 
used a period similar to ours (18 months) (13), the other two a 
period of 1 (26) and 10 years (11).
Taken together, these findings indicate that MRI parameter 
may be more sensitive for assessing disease progression than 
variables assessing clinical functions.
The focus of this study was specifically on cognitive fatigue 
(see Introduction). To put our results into context, we re-
analyzed the data by dividing the MS patient groups into those 
with at least moderate motor fatigue or moderate global fatigue 
according to the FSS and those without fatigue. Using these two 
other fatigue scores, we found several significant differences 
between the healthy control group and one or both MS groups 
concerning performance and MRI parameters, but no interac-
tion effect between GROUP and TIME. This supports the idea 
that cognitive fatigue compared to other fatigue measures is 
especially sensitive for indicating more aggressive inflammatory 
processes at t1. At the same time, it should be noted that there is 
considerable overlap among patients with cognitive fatigue and 
with motor fatigue. Actually, the correlation between cognitive 
fatigue and motor fatigue at t1 was r = 0.81 and that between 
cognitive fatigue and the FSS score r = 0.77. Hence, to analyze 
the meaning of different fatigue measures in more detail larger 
patients groups will be necessary and regression analysis should 
be used.
Multiple sclerosis patients with and without fatigue differed 
from the control group on most MRI parameters, but they did 
not differ from each other. This finding fits earlier negative results 
on the relation of a more global atrophy marker and fatigue (3). 
More specific analyses of the relation between cognitive fatigue, 
as used in this study, and MRI parameters are rare, but a recent 
study of Wilting et al. (27) showed that cognitive fatigue might 
be related to atrophy of the thalamus and not to more global 
variables as brain parenchymal fraction, gray and white matter. 
The other significant finding from our study, arguing for a rela-
tion between age and brain atrophy, does not require additional 
discussion.
We found, as other studies did, that depressive mood did not 
increase over the 17-month period (28). Depressive mood may be 
linked to experiencing relapses and the feeling of losing control 
over the disease. Hence, mood may improve in patients in more 
stable disease conditions, whereas it may deteriorate in patients 
in instable disease conditions.
We tried to analyze whether clinical phenotype played 
a major role for progression. Unfortunately, the number of 
secondary chronic progressive patients was (especially for the 
group without fatigue) too small for statistical analysis. For the 
relapsing-remitting patients (n = 30), there still was a significant 
effect of cognitive fatigue on the number of relapses. They also 
demonstrated a significant higher loss of brain volume. In our 
view, the fact that changes in the lateral ventricle volume and 
the diffusivity of the corpus callosum did not reach statistical 
significance is only due to the reduction of the sample size by 
focusing only on relapsing-remitting patients.
In our view, the fact that changes in the lateral ventricle volume 
and the diffusivity of the corpus callosum did not reach statistical 
significance focusing only on relapsing remitting patients is only 
due to the reduction of the sample size.
Our study clearly has some limitations. First, the number 
of patients and controls was relatively small, but for the type 
of MRI analyses used it is still within the range proposed by 
Harrison et  al. (14) Second, the group of MS patients was 
rather heterogeneous, encompassing patients with relapsing 
remitting and progressive disease courses, with a large age 
range and with and without immunomodulatory treatments. 
Still, we believe it is noteworthy that MS patients with cognitive 
fatigue at t1 showed increased neurodegeneration and suffered 
more relapses during the following 17  months as implied by 
our model for fatigue (2). The relevance of fatigue for changing 
immunomodulatory medication in MS has recently become 
accepted in a consensus paper (29). Our study, if replicated, 
underlines this step toward one additional red flag for recon-
sidering the treatment strategy.
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